Introduction: Immunohistochemistry is a widely used diagnostic technique in pathology, the antibodies used for unvailing a tissue’s origin being made up of proteins, more specifically aminoacids. Malignant peripheral nerve sheath tumors have a distinct immunohistochemistry profile, with great emphasis concerning those with rhabdomyoblastic differentiation being positive for S-100 protein, myogenin, vimentin, CD99, p63, GFAP, caldesmon, desmin, and p53 and Myo-D1 (the later two revealing the striated muscle differentiation). Materials and methods: A case study concerning a patient suffering from a moderately differentiated (G2) non-keratinizing squamous cell carcinoma of the lung highlighted the development of an ndifferentiated sarcomatous proliferation on the left hemithorax, 7 years after the initial external radiotherapy treatment for the malignant lung tumor. Results: The immunohistochemistry analysis of the thoracic wall invasive tumor revealed it to be a malignant peripheal nerve sheath tumor with rhabdomyoblastic differentiation (Triton tumor) with the positivity for the specific aforementioned markers and a proliferation index – Ki67 of 90%. Chemotherapy was the elective treatment which was followed for 1 month, the patient having a rapid downward evolution towards exitus, with a 33 month post-diagnosis survival.

Conclusions: This case was presented due to the rarity and difficulty of the diagnosis, consisting of a rare subtype of malignant peripheral nerve sheath tumor for which there is no therapeutic consensus and with an un-favorable prognosis.

COVID-19 pandemic represents a challenge for entire medical world, with profound implications in daily practice, making a compromise between risk of infection with SARS-COV2 and oncological treatment continuing, in conditions in which must be balanced, for each patient, the risk of infection with COVID-19. We are presenting the recommendations of professional societies and actions take in Radiotherapy Department of „Sf. Ap. Andrei” Emergency Clinical Hospital, Galati in order to limit the spread of COVID-19 infection and concomitant with radiotherapy performing, without compromising the quality of medical act.

Synovial sarcomas (SS) are rare. Less than 5% occur in spine, mediastinum, head and neck and at the retroperitoneal level and in approximately 85% of the cases occur at the level of the soft tissues and extremities. SS metastases are not rare, they occur predominantly at the level of lungs, bones and liver. Standard treatment consists in surgery, ideal, in large excision with negative margins, R0 (when is possible). For unresectable tumors, the therapeutic options include CMT and/or RTE [2]. [...]

Pulmonary artery sarcomas (PA) are uncommon
the first case was documented in 1923 by Mandel Staam. Leiomyosarcoma, fibrosarcoma and rhabdomyosarcoma are the most often histologically confirmed incidences. PA tumor is frequently misinterpreted as thrombo-embolism, as its correct diagnosis is difficult. Magnetic Resonance Imaging (MRI) is superior in providing an accurate diagnosis. Surgery is the only therapeutic strategy which may extend life expectancy. The survival rate in the absence of surgical care is of 1.5 months, survival for 5 years - 6%. In most cases, death occurs by heart failure, and rarely by distant metastases. [...]